Multiplikator Forward P/S: CytoSorbents Corp (CTSO)
Efficient distribution of blood purification systems in Europe and the US ensures a high operating margin for Cytosorbents (CTSO). This forecast P/S chart for Cytosorbents (CTSO) visualizes the current market valuation, where the value 0.50 represents the current metric. This facilitates global dominance in sepsis therapy through the implementation of CytoSorb cartridges, which, amid growing demand in intensive care units, expands the client base worldwide.
Ringkesan rincian data analitis cytosorbents.com (CTSO)
- rega pasar lan target rega analis:
- indikator kapitalisasi bursa perusahaan:
- statistik nilai buku emiten:
- data utang lan likuiditas:
Total Utang marang Modal Cytosorbents|CTSO - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal CytoSorbents Corporation|CTSO - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku CytoSorbents Corporation|CTSO - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Cytosorbents|Rasio cepet cytosorbents.com
- rincian asil keuangan lan kelipatan valuasi:
CTSO - Penghasilan resik perusahaan|Bathi sing dikarepake Cytosorbents|CTSO - Rasio kapitalisasi marang bathi resik|Prakiraan rega marang bathi CytoSorbents Corporation|CTSO - Pangali PEG|Pangali EV/EBITDA CytoSorbents Corporation|CTSO - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Cytosorbents|CTSO - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan cytosorbents.com|CTSO - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Cytosorbents
- indikator dodolan lan pendapatan:
Analisis fundamental perusahaan:CTSO (CytoSorbents Corp.)
Forward P/S compares current market capitalization with expected sales volume, allowing investors to determine the extent to which an asset's value is overpriced relative to future cash flows. The forward price-to-sales analysis for Cytosorbents (CTSO) demonstrates how European revenue offsets the costs of US development, confirming the fundamental resilience of the business during a period of investment pressure.
Karo sapa Cytosorbents saingan
Rasio rega marang prakiraan pendapatan Dexcom DXCM|PEN - Multiplikator forward rega marang pendapatan|Novanta Corp - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Haemonetics Company|INSP: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan PRCT|CNMD (CONMED) - Multiplikator Forward P/S|Pulse Biosciences Inc (PLSE) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S INMD|Multiplikator forward rega marang pendapatan Picard Group PMI|Multiplikator Forward P/S SRDX (Surmodics, Inc.)|Multiplikator Forward P/S senseonics.com SENS|NPCE - Rasio rega marang prakiraan pendapatan|TCMD: Rasio rega marang prakiraan pendapatan|SNWV (SANUWAVE Health, Inc.) - Multiplikator forward rega marang pendapatan|Outset Medical Corp - Rega forward marang dodolan|ELMD (SmartVest) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep lensar.com LNSR|Rasio rega marang prakiraan pendapatan AVITA Medical (RCEL)|profoundmedical.com (PROF) - Prakiraan rega marang pendapatan|Baird Medical - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S EDAP TMS SA EDAP|Bovie Medical - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake IceCure Medical Ltd ICCM|pulmonx.com (LUNG) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TELA (TELA Bio)|Rasio rega marang prakiraan pendapatan Sensus Healthcare Corp|Multiplikator forward rega marang pendapatan Zynex Corp (ZYXI)|Multiplikator Forward P/S ECOR|RBOT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Inspira Technologies IINN|ICU: Kapitalisasi marang prakiraan pendapatan|IRIX: Multiplikator forward rega marang pendapatan|Intelligent Bio Solutions - Rasio rega marang pendapatan sing dikarepake|XAIR: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan profusa.com|Multiplikator forward rega marang pendapatan SSKN|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep glucotrack.com GCTK|Multiplikator forward rega marang pendapatan NAOV (NanoVibronix)|Rasio rega marang pendapatan sing dikarepake VERO|Rasio rega marang prakiraan pendapatan Nuwellis, Inc. NUWE|aethlonmedical.com (AEMD) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ASXC - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Avinger Inc. AVGR|BioSig Technologies, Inc (BSGM) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Cutera Inc (CUTR)|Rasio rega marang prakiraan pendapatan Know Labs, Inc.|NARI: Rega forward marang dodolan|Multiplikator Forward P/S NVRO|Rasio rega marang prakiraan pendapatan RSLS (reshapelifesciences.com)|Multiplikator Forward P/S SILK (Silk Road Medical Inc.)
